Nuclear factor of activated T cells (NFAT1-C) represses the enhancer II and pregenomic promoter (EnII/Cp) of hepatitis B virus (HBV) through its responsive site GGAGA and nullifies the HBx-driven transcriptional activation

RPB5-Mediating Protein Suppresses Hepatitis B Virus (HBV) Transcription and Replication by Counteracting the Transcriptional Activation of Hepatitis B virus X Protein in HBV Replication Mouse Model

Background:

RPB5-Mediating protein (RMP) is associated with the RNA polymerase II subunit RPB5. This protein functionally counteracts the transcriptional activation of Hepatitis B Virus X protein (HBx) by competitively binding to the RPB5; however, the effects of RMP on Hepatitis B virus (HBV) transcription and replication remain unknown.

Objectives:

The purpose of this study was to investigate the effect of RMP on viral transcription and replication in vivo by using the hydrodynamic-based HBV replication mouse model.

Materials and Methods:

Male balb/c mice were transfected with wild type (1.2 wt) or the HBx minus HBV plasmids (1.2x (-)) with or without HBx and RMP, to establish an HBV replication mouse model by hydrodynamic injection through the tail vein. The HBV RNA and HBV DNA replication intermediates (RI) were analyzed in the liver.

Results:

RPB5-Mediating protein could inhibit HBV transcription and replication in groups transfected with the 1.2 wt and HBx. The inhibitory effect disappeared in the 1.2x (-) groups, yet it reappeared in the groups co-transfected with 1.2x (-) and HBx. An inhibitory effect was indicated at a low dose of RMP (0.3 ug, 0.5 ug and 0.7 ug) compared to the control group and groups that had received high doses of RMP.

Conclusions:

Our study demonstrated that a low dose of RMP could inhibit HBV transcription and replication, which is dependent on the appearance of HBx in vivo.

Proteomic analysis of the interleukin-4 (IL-4) response in hepatitis B virus-positive human hepatocelluar carcinoma cell line HepG2.2.15

Hepatitis B virus (HBV) infection is the leading cause of liver cirrhosis and hepatocellular carcinoma worldwide. In recent decades, significant progress toward understanding the molecular virology and pathogenesis of HBV infection has been made. In addition, multiple treatment modalities have been developed for persons with HBV infection. In the present study, we demonstrated that IL-4 inhibits the expression of hepatitis B surface antigen and hepatitis B e antigen in a HBV stably transfected hepatocellular carcinoma cell line (HepG2.2.15). To reveal the anti-HBV mechanism of IL-4 by proteomics, 2-DE and MS technology were utilized to profile global changes in protein expression in HepG2.2.15 cells after IL-4 treatment. A total of 56 differentially expressed proteins were identified in IL-4-treated HepG2.2.15 cells. To find out the interaction of these changed proteins by bioinformatics, signaling network analysis with the STRING tool showed that the identified proteins are primarily involved in transcription and proteolysis. Taken together, these results offer valuable clues for understanding the molecular mechanisms of the IL-4-mediated anti-HBV response.

Cloning and identification of human gene 1 transactivated by hepatitis B virus X antigen

AIM

To study the transactivation effects of HBxAg, and clone the target genes of HBxAg transactivating effects, in order to help understand the mechanism of pathogenesis of HBxAg.

METHODS

Polymerase chain reaction (PCR) was employed to amplify the coding sequence of HBxAg. The hepatoblastoma cell HepG2 was transfected by pcDNA3.1(-) and pcDNA3.1(-)-X, respectively. Total mRNA was purified from the HepG2 cells transfected and suppression subtractive hybridization(SSH) method was used to analyze the differentially expressed DNA sequence between the two groups. The sequences were searched for homologous DNA sequence from GenBank. The new DNA sequence was confirmed and the full-length coding sequence was identified according to the Kozak rule and the existence of polyadenyl signal sequences. Reverse transcription PCR (RT-PCR)was used to amplify the new gene by using mRNA from HepG2 cell as the template. The coding sequence for the new gene was deduced according to the nucleotide sequence.

RESULTS

PCR technique was employed to amplify the coding sequence for HBxAg by using pCP10 plasmid containing whole HBV genome as the template. The recombinant plasmid expressing HBxAg was confirmed by restriction enzyme digestion and sequencing. HepG2 cells were transfected with pcDNA3.1(-) and pcDNA3.1(-)-X by lipofectamine, respectively. Total mRNA was purified from transfected HepG2 cell, and suppression subtractive hybridization method was used for the screening and identification of differentially expressed genes by these two cell groups. After sequencing, each DNA sequence was compared with the genes deposited in the GenBank and the new gene with no homology with known genes in this database was identified. Electric polymerase chain reaction was conducted for the cloning of the full-length DNA of the new gene and in conjunction with Kozak rule and the existence of polyadenyl signal sequence. RT-PCR technique was used to amplify the new gene, named as XTP1, from the mRNA of HepG2 cells. The sequence for the XTP1 gene was deposited into GenBank, and the accession number is AF488828.

CONCLUSION

A new gene named XTP1 which is transac-tivated by hepatitis B virus X protein has been successfully cloned by molecular biological methods. These results pave the way for the study of the molecular mechanism of HBxAg transactivating effects and the development of new therapy for chronic hepatitis B.

N/A

N/A

N/A

N/A